Affiliation:
1. Hematology Unit, Department of Medicine University of Padova Padova Italy
2. Immunology and Molecular Oncology Unit Veneto Institute of Oncology, IOV‐IRCCS Padova Italy
Abstract
SummaryAlthough the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax‐based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA‐CLL13), specifically focus on this topic while real‐word evidence is missing. In our real‐life retrospective study conducted on 61 patients with CLL and treated with venetoclax‐based regimens in any therapeutic line, we documented a remarkable lower progression‐free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.
Funder
Fondazione AIRC per la ricerca sul cancro ETS